Company: ZVRA
Filing Date: 2025-05-08
Form Type: DEFA14A
Source: 0001193125-25-115961
Chunk: 3

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-08
Form: DEFA14A
Chunk 3
---
 on our website: www.zevra.com. i. Orphan Drug Exclusivity ii. Zevra partnered asset; iii. Seeking strategic alternative iv. New Drug Application\Marketing Authorization Application Asset portfolio targeting rare diseases Leverage areas of synergy for commercial portfolio Lean infrastructure that can be leveraged with additional products Multiple upcoming milestones and catalysts Portfolio with commercial and clinical assets U.S. Commercial Partnered Pipeline FDA Approval: Sep 20, 2024 Launch: Nov 21, 2024 IP through 2031 via ODEi FDA Approval: Dec 22, 2022 Launch: Jan 29, 2024 IP through 2036 Receiving royalties and milestones on net salesii IP through 2037 Seeking strategic alternative; Ph. 3 trial readyiii IP through 2037 Ph. 3 trial potentialiii Ph. 3 trial ongoing IP through 2038 Arimoclomol for EMA MAA Submission NPC EMA MAA Submission: Targeting 2H 2025 OLPRUVA® sodium phenylbutyrate for oral suspension Urea Cycle Disorders (UCD) MIPLYFFA® arimoclomol Niemann-Pick Disease Type C (NPC) Delivering Value for Patients Through Our Diversified Portfolio

+62.6% TSR during Neil McFarlane’s Tenure2 +45.1% 1-Year TSR1 Zevra is Outperforming Industry and Broader Market …While Outperforming the Industry and Driving Significant Value for Stockholders Over the Past Year and During Neil’s Tenure 1) Source: Factset Research Systems, Inc. 5/7/24 to 5/7/25 2) Source: Factset Research Systems, Inc. 10/9/23 to 5/7/25

Ownership information via publicly available 13F information as of March 31, 2025 1) Source: Factset Research Systems, Inc. as of 10/8/23 2) Source: Factset Research Systems, Inc. as of 4/24/25 Management Team’s Renewed Focus on Investor Engagement has Heightened Zevra’s Profile with Investors meetings with institutional and retail stockholders during the past year of shares engaged with during Neil’s tenure >50% Advancing a Robust Stockholder Engagement Program sell-side analysts prior to Neil’s tenure sell-side analysts today, including the additions of William Blair, Guggenheim & Citizens 8 5